Genflow Biosciences has launched a groundbreaking gene therapy trial focusing on the SIRT6 gene, aimed at combating age-related decline in dogs.

The trial will involve 28 dogs aged ten and older, who will receive intravenous SIRT6 gene therapy over a six-month period, followed by an additional six months of observation.

This initiative is backed by a $560,000 investment from an institutional supporter, with results expected by the end of 2025.

Researchers will assess the therapy's safety and efficacy by evaluating various factors, including biological age, muscle mass, mitochondrial function, coat condition, and overall well-being.

Dr. Eric Leire, Genflow's CEO, highlights the goal of enhancing the quality of life for pets, which may also provide valuable insights for human medicine.

In addition to the SIRT6 trial, Genflow is developing GF-1002, a gene therapy targeting metabolic dysfunction-associated steatohepatitis, currently in the pre-IND phase and showing promise in preclinical studies.

The company is also exploring treatments for other aging-related conditions, such as sarcopenia and Werner Syndrome, through various collaborations and ongoing research initiatives.